By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Sunovion Pharmaceuticals Inc. 

84 Waterford Drive

Marlborough  Massachusetts  01752  U.S.A.
Phone: 508-481-6700 Fax:


SEARCH JOBS




Collaborations

Acadia  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.

Cubist 





Company News
PARI Pharma's Investigational Closed eFlow Nebulizer System Used In Two Successful Phase 3 Clinical Studies Evaluating Sunovion Pharmaceuticals Inc.'s SUN-101 (Glycopyrrolate) In People With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 6/7/2016 8:28:06 AM
Sunovion Pharmaceuticals Inc.Announces Publication Of Data Evaluating The Long-Term Safety And Tolerability Of Latuda (Lurasidone Hcl) In The Treatment Of Bipolar Depression 5/23/2016 10:42:15 AM
American Thoracic Society And Sunovion Pharmaceuticals Inc. Release Landmark Survey Of Pulmonologists’ Attitudes And Practices With Inhalation Devices For COPD At The ATS 2016 International Conference 5/16/2016 11:29:36 AM
Sunovion Pharmaceuticals Inc. Announces Health Outcomes Data On Exacerbation-Related Hospitalizations That Support The Use Of Brovana (Arformoterol Tartrate) Inhalation Solution In People With Moderate-To-Severe COPD At The 2016 American Thoracic Society Conference 5/16/2016 10:48:36 AM
Sunovion Pharmaceuticals Inc. To Present Data On Latuda (Lurasidone Hcl) At The 169th Annual Meeting Of The American Psychiatric Association 5/12/2016 11:07:40 AM
Sunovion Pharmaceuticals Inc. Presents New Health Outcomes Data Supporting Brovana (Arformoterol Tartrate) Inhalation Solution In People With Moderate-To-Severe COPD At The 2016 American Thoracic Society International Conference 5/4/2016 10:56:57 AM
Sunovion Pharmaceuticals Inc. Announces Positive Results From Two Phase III Clinical Studies Evaluating SUN-101/Eflow (Glycopyrrolate) In People With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 4/27/2016 10:28:06 AM
Sunovion Pharmaceuticals Inc. Announces Results Of Health Outcomes Analyses Supporting The Use Of Aptiom (Eslicarbazepine Acetate) In People With Partial-Onset Seizures At The 68th American Academy of Neurology Annual Meeting 4/15/2016 9:15:24 AM
Sunovion Pharmaceuticals Inc. To Present Data Analyses Supporting Use Of Aptiom (eslicarbazepine acetate) At The 68th American American Academy of Neurology Annual Meeting 4/6/2016 9:42:29 AM
PsychoGenics Inc. Drug Discovery Collaboration With Sunovion Pharmaceuticals Inc. Achieves A Milestone 4/4/2016 10:13:30 AM
12345678910...
//-->